Kategorie: News

In-licensing and product development opportunities available

Similasan’s Dutch subsidiary – Similasan Nederland BV – has marked the one-year anniversary of their re-launch by welcoming three new dry eye products into their portfolio.

Originally launching with four Similasan medical devices for tired, irritated and itchy eyes in 2014, the new ‚Similasan Optimoist’ range is specifically for use with dry eyes. Available now, products include Similasan Optimoist Drops (10mls), Similasan Optimoist Singles (10 x 0.4ml) and a Similasan Optimoist 2-in-1 Dry & Irritated Spray (10mls).

The Netherland’s team, headed up by Harm-Jan Schuurman, an experienced operator in the consumer health products industry have been working closely with GBT Pharma on the re-launch programme.

“GBT Pharma has been instrumental in helping us facilitate our re-entry into the Netherlands,” comments Harm-Jan. “Their experience of helping consumer healthcare companies expand into new markets is unrivalled. From regulatory know-how, to developing new product opportunities, we can count on them to ensure we have the right strategy for success.”

“Harm and his team have achieved a phenomenal amount in a short timeframe, not least re-establishing Similasan among the top five eye care brands in the Dutch market, in the space of only a year,” comments GBT Pharma founder Gian Trepp.

“The future holds many exciting opportunities, as Harm and his team continue on their mission to further drive market growth. As well as working alongside the team to grow the Similasan brand in the Netherlands we will also be offering in-licensing and product development opportunities,” adds Gian.

Parties interested in listing the Similasan eye care range, or to discuss in-licensing opportunities should contact Gian Trepp.

Companies in the Netherlands seeking help and advice with their consumer healthcare strategy are invited to visit OTC-Labs BV – www.otc-labs.nl

OTC labs is a specialist consultancy helping consumer healthcare companies build long term success for their OTC brands.

Dr Gian Trepp, CEO of healthcare market access specialists – GBT Pharma – has co-founded a new company to bolster GBT Pharma’s offering in Europe.

Precision Healthcare has been co-founded along with Matthew Caldwell-Nichols, a seasoned operator in OTC marketing services in the UK and Ireland.

The privately held company will specialise in integrated OTC marketing and sales, regulatory affairs and operations for independent pharmacy, health food channels and key accounts across the UK and Ireland.

“As the 7th largest OTC market in the world, there is huge opportunity for consumer healthcare companies seeking access to UK and Irish markets,” comments Gian.

“However, ensuring you have the right entry strategy and contacts is key to sustainable success. The Precision Healthcare team have been widely active within the pharmacy and OTC healthcare sector in the UK and Republic of Ireland for over twenty years.

“This new partnership will further compliment GBT Pharma’s existing business operations across Latin America, Europe and the rest of the world. In addition, brands seeking to increase their presence in new markets can be assured of having our significant expertise and market know-how at their disposal.”

Matthew Caldwell-Nichols, operations director of Precision Healthcare adds: “From targeted healthcare communications, HCP education and direct marketing to national account management and MHRA licensed warehousing, Precision Healthcare is perfectly placed to reinforce GBT Pharma’s offering in Europe.

«We are also delighted to offer a number of high calibre OTC brands within our portfolio which are available for in-licensing or distribution.”

GBT Pharma has been appointed to secure new business affiliations for two of Refarmed Chemical’s pharmaceutical brands across Latin America.

Innovators in the global pharmaceutical industry for over 40 years, Refarmed’s portfolio of products includes both APIs and finished formulations.

GBT Pharma – specialists in driving international market entry for consumer healthcare companies – has been appointed to identify and secure key distributor partnerships specifically for Refarmed’s Astarte women’s health probiotic food supplement, and their Bacterial Lysate formulation.

Dr Fabio Gatti from Refarmed Chemicals comments: “GBT Pharma’s understanding of the regulatory requirements and their strong network of contacts in this territory made them the ideal partner to introduce these particular brands in this region.”

GBT Pharma founder Gian Trepp added: “Our mission is to identify and secure suitable partners for these high calibre products across Brazil, Columbia, Peru, Chile, Panama, Costa Rica and Ecuador.

“We invite parties interested in securing these particular pharmaceutical registration dossiers together with supply agreements to contact us at GBT Pharma.”

For further information on GBT Pharma or opportunities with the Refarmed brands in Latin America, please contact us. www.gbtpharma.com/contact-us